Insider Buying: Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Director Purchases 10,101,010 Shares of Stock

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Director Aron R. English bought 10,101,010 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were acquired at an average cost of $0.99 per share, with a total value of $9,999,999.90. Following the completion of the purchase, the director now owns 15,467,300 shares in the company, valued at approximately $15,312,627. This represents a 188.23 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Anebulo Pharmaceuticals Price Performance

NASDAQ ANEB opened at $1.70 on Friday. Anebulo Pharmaceuticals, Inc. has a 1-year low of $0.80 and a 1-year high of $3.30. The company has a market capitalization of $44.09 million, a P/E ratio of -5.67 and a beta of -1.09. The business has a 50 day moving average price of $1.57 and a 200 day moving average price of $1.93.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings data on Wednesday, September 25th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.08. On average, research analysts expect that Anebulo Pharmaceuticals, Inc. will post -0.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Benchmark reissued a “speculative buy” rating and set a $8.00 target price on shares of Anebulo Pharmaceuticals in a research note on Tuesday, November 19th.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.